Pulsed heat treatments similarly improve meibomian gland scores
Click Here to Manage Email Alerts
Alcon’s Systane iLux was noninferior to Johnson & Johnson’s LipiFlow for treating dry eye associated with meibomian gland dysfunction at 12 months after treatment, according to a company-sponsored study.
“The present study demonstrated that a single iLux treatment was noninferior to LipiFlow for improving meibomian gland dysfunction scores, with no clinically meaningful differences between groups over 12 months,” Gina Wesley, PhD, BS Optom, of Complete Eye Care of Medina in Minnesota, and colleagues wrote in the study published in Optometry and Vision Science. “Further, clinically relevant improvements in terms of tear breakup time and symptoms of dry eye were noted with both treatments at 12 months.”
The prospective, randomized, parallel-group study compared iLux treatment in 114 participants with LipiFlow treatment in 113 participants, all of whom had meibomian gland dysfunction with evaporative dry eye. To be included, participants had a meibomian gland score (MGS) of 12 or less in lower eyelids, noninvasive tear breakup time of less than 10 seconds and an Impact of Dry Eye on Everyday Life-Symptom Bother module score greater than 16. The primary endpoint was change from baseline MGS at 12 months after a single treatment.
According to study results, MGS improved from baseline for both treatments: 17.4 for iLux compared with 17.8 for LipiFlow, with 95% lower confidence limit of least squares mean difference greater than –5, indicating noninferiority, according to the study. Adverse effects were reported in less than 1% of eyes assessed in the total cohort.
“Our study has not encountered new safety signals or negative biomicroscopy findings with either device,” Wesley and colleagues wrote. “The current study results indicate that the benefit-risk of iLux treatment remains positive.”
Collapse
Read more about
Click Here to Manage Email Alerts